The company, which is only three years removed from one of biotech’s most lucrative IPOs, will cut jobs for a third time and ...

For a small rare disease company with a treatment in the clinic, the toughest challenge isn’t necessarily the science. Often, ...

A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...